Expression profiling of in vivo ductal carcinoma in situ progression models identified B cell lymphoma-9 as a molecular driver of breast cancer invasion
Conclusion:
BCL9 is a molecular driver of DCIS invasive progression and may predispose to the development of basal like invasive breast cancers. As such, BCL9 has the potential to serve as a biomarker of high risk DCIS and as a therapeutic target for prevention of IDC.
Source: Breast Cancer Research - Category: Cancer & Oncology Authors: Hanan ElsarrajYan HongKelli ValdezWhitney MichaelsMarcus HookWilliam SmithJeremy ChienJason HerschkowitzMelissa TroesterMoriah BeckMarc InciardiJason GatewoodLisa MayTherese CusickMarilee McGinnessLawrence RicciFang FanOssama TawfikJeffrey MarksJennifer K Source Type: research
More News: Breast Cancer | Breast Carcinoma | Cancer | Cancer & Oncology | Carcinoma | Carcinoma in Situ | Colon Cancer | Colorectal Cancer | DCIS (Ductal Carcinoma in Situ) | Ductal Carcinoma | Epithelial Cancer | Genetics | HER2 | Lymphoma | Myeloma | Study